7 Analysts Have This to Say About Zymeworks
Portfolio Pulse from Benzinga Insights
In the last 3 months, 7 analysts have provided 12-month price targets for Zymeworks (NASDAQ:ZYME), with an average price target of $13.0, down 18.75% from the previous average of $16.00. The ratings include 3 bullish, 1 somewhat bullish, and 3 indifferent.
June 06, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks' average 12-month price target has decreased by 18.75% to $13.0, with 3 bullish, 1 somewhat bullish, and 3 indifferent analyst ratings in the last 3 months.
The mixed analyst ratings and the decrease in the average price target suggest that there is uncertainty surrounding Zymeworks' stock performance in the short term. While there are more bullish ratings than bearish, the presence of indifferent ratings indicates that the stock's direction is not clear-cut. As a result, the short-term impact on ZYME's stock price is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100